Systematic review / meta-analysis / 2017
Zinc lozenges (>75 mg/day) shortened common cold duration by 33%, with no significant difference between zinc acetate and zinc gluconate or higher doses.
A meta-analysis of seven randomized placebo-controlled trials evaluated zinc lozenges (>75 mg/day) in 575 participants with naturally acquired common colds. Mean common cold duration was 33% (95% CI 21% to 45%) shorter in the zinc groups. Colds were shortened by 40% with zinc acetate (3 trials) and by 28% with zinc gluconate (4 trials), with a non-significant difference of 12 percentage points (95% CI: -12 to +36). Zinc doses of 80-92 mg/day reduced duration by 33% compared to 35% for doses of 192-207 mg/day, a non-significant difference of 2 percentage points (95% CI: -29 to +32).
- Study type
- Meta-analysis of randomized controlled trials
- Who was studied
- 575 participants with naturally acquired common colds across 7 trials
- What was measured
- Duration of the common cold
THE PAPER
Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage.
Hemilä H. JRSM Open, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.